Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Geron Corporation - Common Stock (NQ:GERN)

1.510 -0.040 (-2.58%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Geron Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Geron Stock Is Soaring After Hours: What's Going On?
Geron shares are soaring in Thursday's after-hours session after the company announced that the U.S. Food and Drug Administration's (FDA) Oncologic drugs advisory committee (ODAC) voted in favor of the... 
Via Benzinga
Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS
From Geron Corporation
Via Business Wire
Why Geron Stock Is Falling Today
Geron shares are trading lower Tuesday after a Reuters report stated FDA staff reviewers raised multiple safety concerns over Geron's anemia drug, imetelstat. According to the report, FDA staff said... 
Via Benzinga
Exposures Product Safety
FDA Casts Doubts On Geron's Blood Cancer Drug, But Analyst Sees High Probability For Imetelstat's Potential Approval For MDS Anemia Treatment
The FDA's review of Geron Corporation's imetelstat application for anemia in lower-risk MDS patients. Expert analysis suggests a favorable AdComm vote and potential full FDA approval by the June 16,... 
Via Benzinga
Exposures Product Safety
Geron Earnings Preview
Via Benzinga
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance. 
Via Benzinga
Geron (GERN) Q4 2023 Earnings Call Transcript
GERN earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months. 
Via Talk Markets
Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron to Participate in the B. Riley Securities Virtual Oncology Conference
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS
From Geron Corporation
Via Business Wire
Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis
From Geron Corporation
Via Business Wire
Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS
From Geron Corporation
Via Business Wire
Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors
From Geron Corporation
Via Business Wire
Are You A Trader Or Investor: Biotech Momentum Is Picking Up
ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market. 
Via Talk Markets
Topics ETFs
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron to Participate at Upcoming Investor Conferences in November
From Geron Corporation
Via Business Wire
7 Stocks to Buy if You Anticipate a Hot November
Although the weather might be chilly, a hot November happens to be a recurring theme, which may boost these stocks to buy. 
Via InvestorPlace
Geron (GERN) Q3 2023 Earnings Call Transcript
GERN earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS
From Geron Corporation
Via Business Wire
Geron Corporation Reports Business Highlights and Third Quarter 2023 Financial Results
From Geron Corporation
Via Business Wire
Geron to Announce Third Quarter 2023 Financial Results on November 2, 2023
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
7 Must-Own Small-Cap Stocks That Could Outperform the Market
If you’re ready to absorb significant risk for the chance of ridiculous upside, these small-cap stocks to buy may be just for you. 
Via InvestorPlace
Geron Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS
From Geron Corporation
Via Business Wire
Recent Pullback Buying Opportunity For Blood Cancer Firm Geron: Goldman Sachs
Goldman Sachs has upgraded Geron Corporation (NASDAQ: GERN) to Buy from Neutral, with a p 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.